Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
An alphavirus replicon-derived candidate vaccine against Rift Valley fever virus
Epidemiology and Infection, Volume 137, No. 9, Year 2009
Notification
URL copied to clipboard!
Description
Rift Valley fever virus (RVFV) is a mosquito-transmitted bunyavirus (genus Phlebovirus) associated with severe disease in livestock and fatal encephalitis or haemorrhagic fever in a proportion of infected humans. Although live attenuated and inactivated vaccines have been used in livestock, and on a limited scale in humans, there is a need for improved anti-RVFV vaccines. Towards this goal, Sindbis virus replicon vectors expressing the RVFV Gn and Gc glycoproteins, as well as the non-structural nsM protein, were constructed and evaluated for their ability to induce protective immune responses against RVFV. These replicon vectors were shown to produce the RVFV glycoproteins to high levels in vitro and to induce systemic anti-RVFV antibody responses in immunized mice, as determined by RVFV-specific ELISA, fluorescent antibody tests, and demonstration of a neutralizing antibody response. Replicon vaccination also provided 100% protection against lethal RVFV challenge by either the intraperitoneal or intranasal route. Furthermore, preliminary results indicate that the replicon vectors elicit RVFV-specific neutralizing antibody responses in vaccinated sheep. These results suggest that alphavirus-based replicon vectors can induce protective immunity against RVFV, and that this approach merits further investigation into its potential utility as a RVFV vaccine. © 2009 Cambridge University Press.
Authors & Co-Authors
Heise, Mark T.
United States, Chapel Hill
The University of North Carolina at Chapel Hill
Whitmore, A.
United States, Chapel Hill
The University of North Carolina at Chapel Hill
Thompson, J.
United States, Chapel Hill
The University of North Carolina at Chapel Hill
Parsons, M.
United States, Chapel Hill
The University of North Carolina at Chapel Hill
Grobbelaar, Antoinette A.
South Africa, Johannesburg
National Institute for Communicable Diseases
Kemp, Alan
South Africa, Johannesburg
National Institute for Communicable Diseases
Pawȩska, Janusz Tadeusz
South Africa, Johannesburg
National Institute for Communicable Diseases
Madric, K.
United States, Chapel Hill
The University of North Carolina at Chapel Hill
White, L. J.
United States, Chapel Hill
The University of North Carolina at Chapel Hill
Swanepoel, Robert
South Africa, Johannesburg
National Institute for Communicable Diseases
Burt, Felicity Jane
South Africa, Johannesburg
National Institute for Communicable Diseases
South Africa, Johannesburg
National Health Laboratory Service
South Africa, Bloemfontein
University of the Free State
Statistics
Citations: 11
Authors: 11
Affiliations: 4
Identifiers
Doi:
10.1017/S0950268808001696
ISSN:
09502688
e-ISSN:
14694409
Research Areas
Infectious Diseases